睿昂基因：2025年净利润亏损4988.36万元

Core Viewpoint - Ruiang Gene reported a total operating revenue of 174 million yuan for the fiscal year 2025, representing a year-on-year decline of 28.19% and a net loss of 49.88 million yuan, compared to a loss of 15.76 million yuan in the same period last year. The decline in revenue is attributed to intensified competition in the in vitro diagnostic industry and specific events affecting the company [1]. Group 1 - The total operating revenue for 2025 was 174 million yuan, down 28.19% year-on-year [1] - The net profit loss for the company was 49.88 million yuan, compared to a loss of 15.76 million yuan in the previous year [1] - The decline in revenue is linked to increased competition in the in vitro diagnostic industry and the impact of specific events on the company [1]